

1           10. The method of treatment defined in claim 9 wherein  
2 the plasma homocysteine reducing agent is a compound selected from  
3 the group consisting of folic acid, Vitamin B<sub>6</sub>, Vitamin B<sub>12</sub>, beta-  
4 ine, choline, acetylcysteine, or a metabolic precursor, analogue or  
5 derivative thereof.

1           11. The method of treatment defined in claim 9 wherein  
2 the compound effective to reduce the elevated blood homocysteine  
3 level is folic acid.

1           12. The method of treatment defined in claim 9 wherein  
2 the compound effective to reduce the elevated blood homocysteine  
3 level is Vitamin B<sub>6</sub>.

1           13. The method of treatment defined in claim 9 wherein  
2 the gestagen hormone composition contains a progesterone or an  
3 analogue, derivative or metabolic precursor thereof.

1           14. The method of treatment defined in claim 9 wherein  
2 the patient is taking a gestagen hormone composition for birth  
3 control.

1           15. A method of reducing a risk of thromboembolism  
2 induced by a gestagen hormone upon administration of said hormone  
3 for contraception, hormone replacement therapy, relieving inflamma-  
4 tion, an in vitro fertilization program, dermatological therapy or

5     cosmetological treatment in a patient comprising the step of  
6     administering to the patient simultaneously, previously or subse-  
7     quently to taking the gestagen hormone composition a therapeuti-  
8     cally effective amount of a plasma homocysteine reducing agent.

1             16. The method of reducing a risk of thromboembolism  
2     defined in claim 15 wherein the plasma homocysteine reducing agent  
3     is a compound selected from the group consisting of folic acid,  
4     Vitamin B<sub>6</sub>, Vitamin B<sub>12</sub>, betaine, choline, acetylcysteine, or a  
5     metabolic precursor, analogue or derivative thereof.

1             17. Use of a plasma homocysteine content reducing agent  
2     for the preparation of a composition comprising a gestagen type  
3     hormone for reduction of a thromboembolitic side effect risk  
4     induced by administration of the hormone.

1     *Al*             18. Use of a plasma homocysteine content reducing agent  
2     in combination with a gestagen type hormone for the manufacture of  
3     a medicament for contraception, hormone replacement therapy,  
4     relieving inflammation, an in vitro fertilization program, dermato-  
5     logical therapy or cosmetological treatment. --

---

REMARKS

This preliminary amendment is submitted in order to make  
of record new claims which more sharply focus on the subject matter